{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:23:06Z","timestamp":1762503786727,"version":"3.37.3"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T00:00:00Z","timestamp":1306281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007087","name":"Questcor Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007087","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Genentech, Inc. (South San Francisco, CA)\/Biogen IDEC"},{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Spastic Paralysis Research Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ofatumumab is a fully human anti\u2010CD20 monoclonal antibody in phase II\u2013III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab\u2010allergic child with severe, chronic\u2010relapsing, opsoclonus\u2013myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B\u2010cell expansion and T\u2010cell dysregulation. He had relapsed despite chemotherapy, plasma exchange with immunoadsorption, and resection of ganglioneuroblastoma, detected 3 years after OMS onset. The four ofatumumab infusions (1,195\u2009mg\/m<jats:sup>2<\/jats:sup> total dose) were well tolerated, and CSF B\u2010cell expansion was eliminated. No further relapses have occurred in 3 years, but he remains on low\u2010dose ACTH with neuropsychiatric residuals of OMS. Pediatr Blood Cancer 2012; 58: 988\u2013991. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pbc.23187","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T15:06:56Z","timestamp":1306336016000},"page":"988-991","source":"Crossref","is-referenced-by-count":21,"title":["Ofatumumab for a rituximab\u2010allergic child with chronic\u2010relapsing paraneoplastic opsoclonus\u2013myoclonus"],"prefix":"10.1002","volume":"58","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L.","family":"Travelstead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000212991.64435.f0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20899"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20125"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21264"},{"key":"e_1_2_5_7_2","first-page":"294","article-title":"Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders","volume":"10","author":"Robak T","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06916.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902832679"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0570"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22106"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1542\/peds.2004-0845","article-title":"Immunologic and clinical responses to rituximab in a child with opsoclonus\u2010myoclonus syndrome","volume":"115","author":"Pranzatelli MR","year":"2005","journal-title":"Pediatrics"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1043454204272560"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808324217"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199206000-00002"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23187","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T09:55:29Z","timestamp":1696931729000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,25]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/pbc.23187"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23187","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2011,5,25]]}}}